Abstract Beta-2 adrenergic receptors (β2-ARs) have important roles in the pathogenesis and
treatment of chronic obstructive pulmonary disease (COPD). In recent years, progress has …

Inhaled long-acting bronchodilators, including long-acting β 2 agonists (LABAs) and long-
acting muscarinic antagonists (LAMAs) are the mainstay therapy in the treatment of chronic …

Objective β-Blockers are safe and improve survival in patients with both congestive heart
failure (CHF) and COPD. However, the superiority of different types of β-blockers is still …

Background Coronary heart disease occurs more frequently among patients with chronic
obstructive pulmonary disease (COPD) compared to those without COPD. While some …

Objective To examine the risk of cardiovascular disease (CVD) from tiotropium added to
inhaled long-acting β 2 agonists (LABAs) and inhaled corticosteroids (ICSs) in a nationwide …

Background and purpose: Lung cancer has high global incidence and mortality rates.
Chronic obstructive pulmonary disease (COPD) is strongly associated with lung cancer and …

Chronic obstructive pulmonary disease (COPD) is one of the common and underdiagnosed
diseases with the highest morbidity and mortality in the world. The development of COPD …

Aims Evidence on acute respiratory failure (ARF) from antipsychotics is scant, and only 1
population‐based study examined this drug safety issue in chronic obstructive pulmonary …

Objectives To integrate evidence from randomised controlled trials (RCTs) and
observational studies on the efficacy of inhaled treatments for chronic obstructive pulmonary …

Chronic obstructive pulmonary disease (COPD) is the third-most deadly disease in the world
and will be a major healthcare problem for decades to come. Its etiology is mainly related to …